

# High Recovery Method of HybridSPE®-Phospholipid for Cleanup of Biological Samples Prior to LC-MS Analysis

Xiaoning Lu and Michael Ye

Supelco, Div. of Sigma-Aldrich, Bellefonte, PA 16823 USA



[sigma-aldrich.com](http://sigma-aldrich.com)

T411056

# Outline:

Brief Overview of HybridSPE

Case studies of low-rec compounds:

1. Strong Bases
2. Strong Acid
3. Neutral hydrophobic
4. Acid-labile compound


Summary

# Overview of HybridSPE-Phospholipid

Functions: Protein precipitation and Phospholipid removal

- ✓ In-well protein precipitation via the addition of organic solvents, e.g. Acetonitrile and MeOH.
- ✓ PLs removal by proprietary zirconia-modified silica particles.
- ✓ The operation is both simple and fast.

# How Are Proteins and Phospholipids Removed?



# **Critical Conditions: Protein Crashing Solvent and Additives**

**Protein precipitation efficiency**

**Phospholipid removal**









**Compound recovery**

**Primary method: ACN w/ 1% formic acid**

**One of the common methods used in bioanalyses. The recommended method when the product was launched.**


**Good recovery from HybridSPE for many of our tested compounds.**

# Case 1: Strong Bases

Eluate 8,3 ng/mL	Structure Formula												
	composition %			Recovery [%]									
Sample Name	ACN	MeOH	Formic Acid	Amitriptylin	Nortriptylin	Citalopram	Clozapin	Trazodon	Mirtazapin	Desmethyl mirtazapin	Olanzapin	Risperidon	Hydroxy-risperidon
Standard				100	100	100	100	100	100	100	100	100	100
Probe F8	100	0	1.0	106	106	95	88	93	38	65	13	42	84
Probe F9				101	111	95	91	97	42	70	13	45	85
Probe F10			1.5	105	113	99	88	97	41	66	17	45	81
Probe F11				110	112	101	96	101	45	72	17	52	85
Probe F12			2.0	89	95	86	57	85	20	45	7	18	63
Probe G1				110	115	106	104	93	50	56	39	68	92
Probe G2	90	10	1.0	77	82	74	68	73	33	51	13	38	60
Probe G3				95	102	90	87	88	45	64	15	53	75
Probe G4			1.5	77	85	73	57	76	24	48	7	25	60
Probe G5				94	102	90	77	93	40	61	24	48	74
Probe G6			2.0	53	60	52	21	53	7	20	3	7	30
Probe G7				92	97	86	71	86	33	61	16	34	72
Probe G9			70	30	1.0	73	81	70	58	75	30	47	12
Probe G10	1.5	92			100	84	71	90	33	60	15	34	70
Probe G11		75			82	67	57	75	33	46	15	39	59
Probe G12	2.0	72			80	68	37	71	16	37	5	16	48
Probe H1		76			85	71	66	78	42	49	29	52	60
Probe H2	50	50			1.0	91	97	80	80	90	40	66	32
Probe H4			1.5	57	65	51	35	61	15	30	6	16	36
Probe H5				63	71	58	53	65	35	42	24	45	51
Probe H6			2.0	65	75	63	47	68	25	36	19	32	47
Probe H7				62	69	56	40	65	23	33	16	29	42

# Case 1: Strong Bases


NR3(+) Vs Recovery:



Risperidone

42%


2 -NR3 groups



Mirtazapine

38%

3 -NR3 groups




Olanzapine,

13%

3 -NR3 groups

# Improved Recovery with Less – NR3 Group






# Improved Recovery with Salts

Recovery of Standard Without Matrix Plasma					
Analyte	MeCN/1% FA	MeOH	MeOH/1% NH <sub>4</sub> FA	MeOH/1% NH <sub>4</sub> Cl	MeOH/150 mM NaCl
Mirtazapine (266/195)	0.0	13.2	96.5	38.2	99.0
Risperidone (411/191)	0.0	10.4	99.1	111.6	64.0
Olanzapine (313/256)	0.0	13.6	89.4	NO experiment	74.0

## Learning from Case 1- Strong Bases:

- ❖ The low recovery bases typically have at least one  $-NR_3$  groups.
- ❖ The low recovery very likely due to cation-exchange interactions with the Silica support.
- ❖ The ion-exchange interactions were effectively suppressed by the addition of salts such as  $NH_4FA$ ,  $NH_4Cl$ , and  $NaCl$ .
- ❖ Methanol is a better solvent for the salt additives than  $MeCN$ .

## Case 2: Strong Acid




Acamprosate, Zero recovery from HybridSPE plates or cartridges !

## High Recovery with the Addition of $\text{NH}_4\text{ClO}_4$

Recovery of Acamprosate std from HybridSPE 96-well plate		
Conditions	Recovery (%)	Standard Deviation (%)
ACN/1% formic acid	19.0	1.7
MeOH/1% ammonium formate	43.3	5.2
MeOH/2% ammonium formate	54.2	3.3
MeOH/5% ammonium formate	6.5	0.9
MeOH/1% ammonium malate	39.1	3.5
<b>MeOH/100mM ammonium perchlorate</b>	<b>84.2</b>	<b>8.1</b>
<b>MeOH/200mM ammonium perchlorate</b>	<b>100.7</b>	<b>8.8</b>


# High Recovery with Fast Separation of Strong Acid



## Case 3: Neutral Hydrophobic

### Drospirenon problems:


1. Low Rec
2. Variation of recovery 15-30%



Drospirenone, C<sub>24</sub>H<sub>30</sub>O<sub>3</sub>, MW 366.227 (mono),  
ACD/LogD (pH 7.4): 3.16  
MRM: 367.2→97.1 or 91

## Possible Causes:

1. Low solubility in MeCN
2. Strong affinity to transporter proteins




Drospirenone, C<sub>24</sub>H<sub>30</sub>O<sub>3</sub>, MW 366.227 (mono),  
ACD/LogD (pH 7.4): 3.16  
MRM: 367.2→97.1 or 91

# Nice Recovery and Reproducibility with MeOH/1%NH<sub>4</sub>FA

Replicate	Recovery of Drospirenone Spiked in Rat Plasma	
	10 ng/mL spike	60 ng/mL spike
1	89.9	91.9
2	87.0	93.7
3	91.8	88.4
4	96.9	93.5
5	91.9	90.4
6	91.0	87.4
7	94.2	87.5
8	97.0	88.0
9	86.1	87.5
10	87.0	87.9
11	84.0	87.8
12	86.9	87.7
Avg	90.3	89.3
STD	4.3	2.4
%CV	4.7	2.7



## Case 4: Acid-labile Compounds



Carboplatin:

<u>Recovery</u>	<u>Protein Precipitation Conditions</u>
20%	ACN/1% formic acid
85%	MeOH/1% NH <sub>4</sub> FA

## Summary of Learning:


**Addition of salt additives, e.g.  $\text{NH}_4\text{FA}$  and  $\text{NH}_4\text{ClO}_4$ , is necessary to reduce the non-specific bindings, and therefore improve the recoveries of both strong acids and bases.**

**Many of the salt additives are not soluble in MeCN, but soluble in MeOH.**





**MeOH/salts may be a better protein crashing condition.**

# Protein Precipitation in ACN and Methanol



**Comparable Results with Methanol.**

# Phospholipid Removal – PCs at 184 and 104



## **Conclusion:**

### **MeOH/Salt additive is an alternative protein crashing method for HybridSPE**

- ❖ **Comparable efficiency in protein precipitation and phospholipid removal.**
- ❖ **Improved recovery for strong bases and acids.**
- ❖ **Improved reproducibility for low soluble compounds in MeCN**
- ❖ **Improved recovery for acid-labile solutes.**
- ❖ **Alternative solvent if MeCN shortage is a concern.**

# Acknowledgement

Collaborations:  
Max Planck Institut  
Bayer-Germany  
Covance

*Thanks!*